Importance Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of
patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis …

Amyloidosis is a group of disorders characterized by a misfolded protein that deposits in
organs and compromise their function. Clinician should have a high index of suspicion …

OBJECTIVE To examine whether the outcome of patients with primary systemic amyloidosis
(AL) has improved over time and to identify predictors of early mortality in patients with AL …

Background Systemic amyloidosis is a multi-system disease caused by fibrillary protein
deposition with ensuing dysfunction of the affected organ systems. Its diagnosis is often …

Background: Amyloidosis has been a mystery for centuries, but research of the last decennia
has clarified many of the secrets of this group of diseases. A protein-based classification of …

Systemic amyloidosis is caused by misfolding and extracellular deposition of one of an ever-
growing list of circulating proteins, resulting in vital organ dysfunction and eventually death …

Objective: Systemic AA amyloidosis is a serious complication of chronic inflammation;
however, there are relatively few published data on its incidence. We investigated the …

Amyloid is an abnormal extracellular fibrillar protein deposit in the tissues. In humans, more
than 25 different proteins can adopt a fibrillar conformation in vivo that results in the …

The recent decades have ushered in considerable advancements in the diagnosis and
treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve, AL …

The combination of cyclophosphamide/bortezomib/dexamethasone (CyBorD) showed early
promise of high rates of hematologic responses tempered by studies showing the inability to …